ROCKAWAY, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness ...

ROCKAWAY, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness ...

ROCKAWAY, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has been recognized by the Financial Times as one ...

Record revenue for Q3 2025 of $8.7 million, a 33% increase over Q3’2024 Year-to-date revenue of $22.8 million, a 26% increase compared to the first nine months of 2024 Total Cash of $13.2 million as ...

Key Points Interested in electroCore, Inc.? Here are five stocks we like better. electroCore said it is targeting at least 30% year-over-year revenue growth while pushing toward cash-flow breakeven, ...

ROCKAWAY, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) ("electroCore" or the “Company”), a commercial-stage bioelectronic medicine Company and wellness company, today ...

ROCKAWAY, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic and wellness company, today announced that it has been completely vindicated in the ...

electroCore strengthens its extensive intellectual property portfolio with issuance of two new U.S. patents, extending protection on core products and applications ROCKAWAY, N.J., March 30, 2026 ...

ROCKAWAY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) ("electroCore" or the “Company”), a bioelectronic technology company, today announced full year 2025 financial ...

electroCore Supports Results of Lancet Paper Highlighting the Benefits of Vagus Nerve Stimulation for Stroke Patients electroCore anticipates results of the company’s two clinical studies on ...